Vascular-guided IRE for tumor ablation and organ scaffolding
This technology uses irreversible electroporation (IRE) — a method that delivers precisely calibrated electrical pulses to destroy cells — delivered directly through a tissue's existing blood vessels rather than through external probes. For treating tumors, electrical current is threaded through the vasculature to kill cancer cells deep inside organs that are otherwise hard to reach surgically. The same technique can also be applied outside the body to strip all cells from a donor organ while leaving the blood vessel network intact, creating a clean biological scaffold that a patient's own cells can repopulate with minimal immune rejection risk.
What you could build
A catheter-based IRE delivery system for interventional oncology targeting tumors in highly vascularized organs like the liver or pancreas, sold to hospital systems and interventional radiology departments; a companion ex vivo decellularization platform for organ biobanks and tissue engineering companies producing transplant-ready scaffolds.
Who in Virginia should care
Virginia health systems (Inova, VCU Health, UVA Medical Center) with active interventional oncology and transplant programs, plus biotech firms in the Northern Virginia and Richmond corridors working on regenerative medicine.
Readiness: Lab validated
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- —
- Granted
- January 21, 2020
- Status
- Granted patent
- Patent number
- 102806
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.